DA32 Life Science Tech Acquisition Corp. (DALS) has an overall financial health rating of A- with a composite score of 0 out of 5.
This suggests the company faces some financial challenges worth monitoring. Rating as of 2023-07-28.
| Date | Rating | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2023-07-28 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2023-07-27 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2023-07-26 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2023-07-25 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2023-07-24 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2023-07-21 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2023-07-20 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2023-07-19 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2023-07-17 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2023-07-14 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2023-07-13 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2023-07-12 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 |
